Volume 25, Number 1—January 2019
Research
Effects of Antibiotic Cycling Policy on Incidence of Healthcare-Associated MRSA and Clostridioides difficile Infection in Secondary Healthcare Settings
Table 4
Changes in resistance patterns of healthcare-associated methicillin-resistant Staphylococcus aureus clinical isolates, Northern Ireland, UK*
Antibiotic comparison |
AAH, no. resistant isolates/total tested (%) | CH, no. resistant isolates/total tested (%) | |||||
---|---|---|---|---|---|---|---|
Preintervention resistance |
Intervention resistance |
p value |
Preintervention resistance |
Intervention resistance |
p value |
||
Preintervention vs. intervention | |||||||
Amoxicillin/clavulanic acid | 2/2 (100) | 2/2 (100) | NA | 2/2 (100) | 0 | NA | |
Piperacillin/tazobactam | 1/1 (100) | 1/1 (100) | NA | 1/1 (100) | 0 | NA | |
Ciprofloxacin | 66/66 (100) | 77/78 (98.7) | 0.99 | 31/31 (100) | 33/34 (97.1) | 0.17 | |
Erythromycin |
54/70 (77.1) |
69/80 (86.3) |
0.18 |
23/32 (71.9) |
22/35 (65.9) |
0.43 |
|
Intervention vs. postintervention | |||||||
Amoxicillin/clavulanic acid | 2/2 (100) | 2/2 (100) | NA | NR | NR | NR | |
Piperacillin/tazobactam | 1/1 (100) | 0 | NA | NR | NR | NR | |
Ciprofloxacin | 77/78 (98.7) | 27/27 (100) | 0.74 | NR | NR | NR | |
Erythromycin | 69/80 (86.3) | 23/28 (82.1) | 0.40 | NR | NR | NR |
*In AAH (antibiotic cycling policy) and CH (standard antibiotic policy), the preintervention period was November 2011–September 2013, and the intervention period was October 2013–September 2015. In AAH, the postintervention period was October 2015–September 2016. AAH, Antrim Area Hospital; CH, Causeway Hospital; NA, no isolates tested against amoxicillin/clavulanic acid and piperacillin/tazobactam; NR, data not recorded.
1Current affiliation: Craigavon Area Hospital, Craigavon, Northern Ireland, UK.
Page created: December 17, 2018
Page updated: December 17, 2018
Page reviewed: December 17, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.